Views & Analysis The biggest pharma stories of 2016 so far The top 10 pharma milestones of the year to date.
News German watchdog criticises EMA adaptive pathways approval Cost effectiveness agency critical of real world evidence plans
Views & Analysis The EMA’s Adaptive Pathways: are safety concerns exaggerated... Companies still need to provide a compelling case for efficacy
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
